Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 60S acidic ribosomal proteins P0 and P1 are essential components of the eukaryotic ribosome's lateral stalk, a dynamic structure critical for protein biosynthesis [1, 3]. P0 serves as the anchor for the stalk, binding directly to the 28S ribosomal RNA, while P1 (along with P2) forms heterodimers that attach to P0 to complete the pentameric P-complex [5, 12]. This stalk is primarily responsible for the recruitment and activation of GTP-dependent translation elongation factors, such as eEF-1 and eEF-2, which are necessary for the movement of the ribosome along mRNA [8, 13]. In clinical contexts, these proteins are significant autoantigens in Systemic Lupus Erythematosus (SLE), where the presence of anti-ribosomal P antibodies is a highly specific marker for the disease and its neuropsychiatric manifestations [2, 13]. Furthermore, P0 and P1 are frequently overexpressed in various malignancies, including breast, liver, and lung carcinomas, where they contribute to increased translational capacity and tumor progression [1, 9]. They also serve as the critical docking site for ribosome-inactivating toxins like ricin and Shiga toxin, which exploit the P-stalk to access the sarcin-ricin loop and halt cellular protein production [13, 17]. Research into targeting these proteins for cancer therapy is ongoing, though their essential role in global translation presents significant challenges for achieving therapeutic selectivity [9, 15].
Toxins like ricin and Shiga toxin bind to the conserved C-terminal domain of the P-stalk proteins to gain access to the sarcin-ricin loop of the 28S rRNA, where they exert N-glycosidase activity to inhibit translation [13, 17].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S acidic ribosomal protein P0 and P1 (RPLP0/RPLP1).